Table 3.
Co‐detections1 | Total | BioFire (+)/QIAstat (+) | BioFire (+)/QIAstat (−) | BioFire (−)/QIAstat (+) | |
---|---|---|---|---|---|
SARS‐CoV‐2 & | HRV/HEV | 3 | 3 | ||
HRV/HEV & HBoV2 | 1 | 1 | |||
IV‐A & RSV | 1 | 1 | |||
HRV/HEV | 2 | 2 | |||
IV‐A | 1 | 1 | |||
HAdV | 1 | 1 | |||
HPIV | 1 | 1 | |||
IV‐A & HPIV | 1 | 1 | |||
SARS‐CoV‐2 & | IV‐A | 2 | 2 | ||
HCoV‐229E | 1 | 1 | |||
HRV/HEV | 1 | 1 | |||
IV‐A | RSV | 1 | 1 | ||
HAdV | 1 | 1 | |||
HPIV & HCoV | 1 | 1 | |||
RSV & HRV/HEV & HBoV2 | 1 | 1 | |||
HAdV | HRV/HEV | 3 | 3 | ||
RSV | 1 | 1 | |||
hMPV | 1 | 1 | |||
HAdV | RSV | 2 | 2 | ||
HRV/HEV | 2 | 2 | |||
HRV/HEV & RSV | 1 | 1 | |||
hMPV & C. pneumoniae 3 | 1 | 1 | 1 | ||
HCoV | HRV/HEV | 2 | 2 | ||
HCoV & HPIV | 1 | 1 | |||
HPIV & HBoV2 | 1 | 1 | |||
M. pneumoniae | 1 | 1 | |||
HCoV | HPIV & HRV/HEV | 1 | 1 | ||
RSV | HRV/HEV | 1 | 1 | ||
HRV/HEV & HBoV2 | 1 | 1 | |||
HRV/HEV & HCoV | 1 | 1 | |||
HCoV | 1 | 1 | |||
RSV | HRV/HEV | 1 | 1 | ||
HRV/HEV | hMPV | 3 | 3 | ||
M. pneumoniae | 2 | 2 | |||
C. pneumoniae | 1 | 1 | |||
HRV/HEV | M. pneumoniae | 1 | 1 | ||
hMPV | 1 | 1 | |||
M. pneumoniae & HPIV | 1 | 1 | |||
B. pertussis | 1 | 1 | |||
Total | 51 | 24 | 23 | 5 |
Abbreviations: FN, false negative; FP, false positive; HAdV, human adenovirus; HCoV, human coronavirus; hMPV, human metapneumovirus A and B; HPIV, human parainfluenzavirus; HRV/HEV, human rhino‐/enterovirus; IV‐A, influenzavirus A; IV‐B, influenzavirus B; k, kappa score; MERS, Middle East respiratory syndrome coronavirus; NPV, negative predictive value; PPV, positive predictive value; RSV, respiratory syncytial virus A and B; TN, true negative; TP, true positive.
Respiratory pathogens missed by the respective other multiplex panel test are marked with an underline.
HBoV is not included in the BioFire‐RP2.1 multiplex panel test; rated as double infection in Figure 2.
BioFire‐RP2.1 multiplex panel test missed the HAdV detection, while QIAStat‐Dx‐RP2.0 missed the C. pneumoniae detection.